In essential hypertension, endothelial dysfunction has been documented many times and correlates with prognosis. The influence of the renin-angiotensinaldosterone system (RAAS) on endothelial dysfunction has also been studied. The present study investigated the duration of the effects of RAAS-blocking drugs on endothelial function in 44 consecutive, never-treated, outpatients with mild to moderate hypertension. Patients (11 per group) received an angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day) or an angiotensinconverting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day). If target blood pressure (< 140/90 mmHg) was not achieved, 12.5 mg/day hydrochlorothiazide was added. Endothelial function, assessed by measuring brachial artery diameter, did not change significantly after 6 weeks, 1 year or 3 years of treatment in any group. Across all groups, endothelium-dependent and -independent vasodilation increased significantly after 6 weeks but, after 1 year, decreased below baseline and was at a similar level after 3 years; groups did not differ significantly. Both ACEi and ARB had similar effects on endothelial function; improvement occurred at the start of treatment but was not maintained. Endothelial dysfunction may be a resistant or irreversible feature of hypertension, requiring high doses of antihypertensive drugs and above-average patient compliance.
Introduction
Endothelial dysfunction has been documented many times in studies of essential hypertension, 1,2 and correlates with overall prognosis. 3, 4 Special attention has been given to the effect of the reninangiotensin-aldosterone system (RAAS) on endothelial function. 5 -8 Two studies with Long-term effects of RAAS-blocking drugs on endothelial dysfunction follow-up periods > 6 months have reported the effect of RAAS-blocking drugs on flowmediated vasodilation (FMD). Muiesan et al. 9 followed 58 hypertensive patients on combination therapy and found improvement in FMD compared with baseline at 12 months. Ghiadoni et al., 10 in a study of 168 hypertensive patients, found improvement in FMD at 6 months in those who received perindopril only, whereas all treatment arms showed similar reductions in blood pressure (BP). In the present study, we investigated the short-and long-term effects on endothelial function of drugs with blocking effects on the RAAS.
Patients and methods

PATIENTS AND STUDY DESIGN
The study included consecutive never-treated mild-to-moderate hypertensives, defined according to the 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension (BP ≤ 170/95 mmHg), 11 who were attending a single (Department of Internal Medicine, Istanbul Faculty of Medicine, University of Istanbul) outpatient clinic. Patients were randomized into four treatment arms to receive either an angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day) or an angiotensin-converting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day). Target BP was < 140/90 mmHg; if this was not achieved, 12.5 mg/day hydrochlorthiazide (a diuretic agent) was added to the regimen. Endothelial function was measured at baseline and after 6 weeks, 1 year and 3 years of treatment. The study was approved by the ethics committee of the Istanbul Medical Faculty, University of Istanbul (No. 2005-338) . Both written and verbal consents were taken from the patients prior to their participation.
ASSESSMENT OF ENDOTHELIAL FUNCTION
The brachial artery was imaged with a commercially available ultrasound system (System FiVe ® ; VingMed Technology, Horten, Norway) using a 10.0 MHz linear phasedarray ultrasound transducer, positioned longitudinally just above the antecubital fossa, as described previously. 12, 13 A BP cuff was wrapped around the upper arm, inflated to 250 mmHg and held for 5 min to induce ischaemia. The cuff was released and the brachial artery diameter was measured every minute for 5 min to assess maximal endothelium-dependent vasodilation (EDD) in response to reactive hyperaemia. When the vessel diameter had returned to the baseline value (after approximately 7 -10 min), endothelium-independent vasodilation (EID) was assessed every minute for 5 min after sublingual administration of 0.5 mg nitroglycerine. Vessel diameter was measured at end-diastole, coincident with onset of the R-wave seen on a simultaneously obtained electrocardiogram trace. When making these measurements particular attention was given to the patient's age, menstrual cycle, exercise level, concomitant drugs taken, food ingested, sympathetic stimuli and the temperature of the laboratory, as recommended by guidelines of the International Brachial Artery Reactivity Task Force. 13 Vasodilation was calculated using the following formula: percentage EDD or EID = 100 × (pBAD − bBAD)/bBAD, where pBAD is peak brachial artery diameter after intervention and bBAD is baseline brachial artery diameter.
Intra-and inter-observer variabilities of the measurements in our laboratory were 1 -3%.
STATISTICAL ANALYSIS
Numerical data are given as mean ± SD and non-numerical data are given as counts and AB Sozen, MS Kayacan, T Tansel et al.
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percentages. Demographic data from the four patient groups were analysed by oneway analysis of variance (ANOVA) for numerical variables. Post hoc analysis of variables for which significant effects were found in one-way ANOVA was carried out with the Scheffé method. The χ 2 test was used to compare non-numerical data. When the minimal expected frequency within a cell was < 5 in 4 × 2 contingency tables, groups were combined until expected frequencies in cells were > 5; this was usually done by combining the two ACEi or the two ARB. Yates' correction was performed using 2 × 2 tables; if assumptions were still violated in these tables, Fisher's exact test was done.
Repeated-measures ANOVA was used for repeated measures of endothelial function. The within-subject factor was the four measurements of endothelial function, and the between-subject factor was the use of either ACEi or ARB. Box's M test was used to test whether the covariance matrices were equal. Wilke's lambda was used to test the significance of the multivariate model. Circularity of the variance-covariance matrix for within-subject effects was tested with Mauchly's test of sphericity; if sphericity could not be assumed, the Greenhouse-Geisser epsilon method of correcting the number of degrees of freedom was used. Between-subject effects were assessed by ANOVA and the equality of error variance was tested with the Levene test. Comparison between EDD and EID measured at different time intervals for the ARB and ACEi patient groups was carried out with the paired samples Student's t-test. A P-value < 0.05 was accepted as showing statistical significance.
Results
Forty-four consecutive patients (n = 11 per group) were assigned to receive treatment with one of the four RAAS-blocking agents: ARB, irbesartan 300 mg/day or valsartan 160 mg/day; ACEi, fosinopril 10 mg/day or quinapril 20 mg/day. The groups were similar in terms of demographic and cardiac risk factors at baseline, except significantly more women than men received an ARB (P = 0.031; Table 1 ) and the irbesartan group had significantly lower uric acid (P = 0.004) and haemoglobin levels (P = 0.015) compared with patients receiving fosinopril (Table 2) . Target BP was reached in all patients, with two patients in each group requiring the addition of 12.5 mg/day hydrochlorothiazide. At year 3 follow-up, the study was stopped in six patients because of cough, in 12 patients because of insufficiency of monotherapy and in one patient who wished to become pregnant. No patient had any cardiovascular complications, possibly because of the relatively young age of the cohort. There was no significant change in basal brachial artery diameter across the study period which shows that the measurements were being undertaken under consistent favourable conditions. In all four treatment groups, EDD and EID increased significantly, with amelioration in endothelial function, after 6 weeks' treatment, followed by a decrease below baseline values after 1 year's treatment, which was accompanied by deterioration in endothelial function. After 3 years' follow-up, the values were further decreased from those recorded after 1 year, with accompanying deterioration in endothelial function. The levels of statistical significance for comparisons of EDD and EID within the ACEi and ARB groups are given in Table 3 . There were no statistically significant between-group differences at any time during follow-up.
Discussion
The results of the present study indicate that Long-term effects of RAAS-blocking drugs on endothelial dysfunction drugs with blocking effects on the RAAS improved endothelial dysfunction in the short term, but not in the long term. We found improved endothelial function at 6 weeks after treatment, but this fell below baseline at the 1-and 3-year measurements. There was no worsening in BP control. We believe that our failure to show sustained improvement in endothelial function is at variance with the literature and needs explanation.
The long-term effect of RAAS-blocking drugs on FMD has previously been examined in two studies. In one study, 58 hypertensive patients receiving combination therapy were Statistical analysis was by post hoc analysis of variables across the four groups using one-way analysis of variance (ANOVA), followed by the Scheffé method where ANOVA indicated at least one group was statistically significant. HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cell; NS, no statistically significant difference (P > 0.05).
TABLE 2:
Baseline biochemical variables of patients with mild to moderate hypertension who were treated with drugs that block the renin-angiotensin-aldosterone system (n = 11 per group) AB Sozen, MS Kayacan, T Tansel et al. Long-term effects of RAAS-blocking drugs on endothelial dysfunction followed for 12 months, and improvement persisted to 12 months. 9 In another study, Ghiadoni et al. 10 found FMD improvement at 6 months in the perindopril group only, though BP was reduced similarly in all treatment arms. There may be discordance between the BP-lowering effect and the amelioration of endothelial function, as reported by Ghiadoni et al. 10 and indicated by our present results.
The RAAS-blocking drugs have acute effects on the endothelium. Their known long-term effects may be due other protective properties within the vascular system, as seen in the BENEDICT and EUROPA studies. 14, 15 Certainly, in the BENEDICT study, the effect of verapamil (sustained release) plus trandolapril and that of trandolapril alone exceeded expectations, based on changes in BP alone. 14 Optimal BP and metabolic control were achieved in the group of normoalbuminuric patients who had type 2 diabetes and hypertension: the onset of microalbuminuria was significantly delayed. 14 In Turkey, patients are prescribed medications for a maximum of 3 months under the country's social insurance arrangements so, in the present study, BP was only measured every 3 months. These measurements implied that BP was apparently 'under control', however endothelial function continued to deteriorate after a brief amelioration which may indicate that stricter blood pressure control, hence better compliance with treatment, may be required for the protection of endothelial function. Although we believe AB Sozen, MS Kayacan, T Tansel et al. Long-term effects of RAAS-blocking drugs on endothelial dysfunction that patients' BP was regulated in the present study and that they took their study drugs, measurements taken only every 3 months cannot confirm this.
Hypertension is clearly a progressive condition: for example, we observed that 12 of the patients (27%) required additional drugs to control it. Some pathophysiological aspects of hypertension may be better treated with antihypertensive drugs than others. For example, it may be that endothelial dysfunction is a resistant facet of hypertension that requires doses of antihypertensive agents that are higher than those required to control BP. Panza et al. 16 found that endothelial dysfunction persisted after antihypertensive treatment had produced a clinical effect. They hypothesized that such endothelial dysfunction may either be primary or become an irreversible condition once the hypertensive process is established. Additionally, two small studies suggested that very high doses of ARB may exert a significantly greater antiproteinuric action than standard doses, with no increment in the antihypertensive effect. 17, 18 In conclusion, our findings indicate that there was no difference between the effects of ACEi and ARB on endothelial function. Improvements in endothelial function were seen soon after treatment began, but were limited to the short term. Endothelial dysfunction may be a resistant or irreversible feature of hypertension that may require 3.4 ± 0.5 3.4 ± 0.6 3.5 ± 0.5 3.6 ± 0.4 Angiotensin receptor blockers Irbesartan 300 mg/day EDD (%) 13.2 ± 3.9 16.4 ± 4.3** 14.6 ± 5.9 † † 11.3 ± 5.2** , † † †, ‡ EID (%) 18.6 ± 5.3 21.3 ± 5.7* 18.0 ± 6.3* , † † 13.5 ± 5.8*** , † † †, ‡ ‡ Basal (mm)
3.4 ± 0.5 3.4 ± 0.6 3.4 ± 0.6 3.3 ± 0.4 Valsartan 160 mg/day EDD (%) 17.9 ± 6.5 20.8 ± 6.9** 13.1 ± 5.7 † † 11.8 ± 3.6** , † † †, ‡ EID (%) 20.4 ± 4.3 23.1 ± 8.4* 15.4 ± 5.8* , † † 14.1 ± 4.5*** , † † †, ‡ ‡ Basal (mm)
3.6 ± 0.5 3.5 ± 0.5 3.5 ± 0.5 3.6 ± 0.3 Student's t-test: *P < 0.05, **P < 0.01, ***P < 0.001 for EDD or EID versus baseline within each specific treatment group; † † P < 0.01, † † † P < 0.001 for EDD or EID versus 6 weeks within each specific treatment group; ‡ P < 0.05, ‡ ‡ P < 0.01 for EDD or EID versus 1 year within each specific treatment group; all other within-treatment group comparisons were not statistically significant (P > 0.05). EDD, endothelium-dependent vasodilation; EID, endothelium-independent vasodilation; 'basal', basal brachial artery diameter.
TABLE 3: Effects of drugs that block the renin-angiotensin-aldosterone system on endothelial function as assessed by measuring brachial artery diameter during 3 years of follow-up in patients with mild to moderate hypertension (n = 11 per group)
